0001017491-20-000001.txt : 20200914 0001017491-20-000001.hdr.sgml : 20200914 20200914160211 ACCESSION NUMBER: 0001017491-20-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20200914 DATE AS OF CHANGE: 20200914 EFFECTIVENESS DATE: 20200914 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SEELOS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001017491 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870449967 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-375447 FILM NUMBER: 201173197 BUSINESS ADDRESS: STREET 1: 300 PARK AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: (646) 998-6475 MAIL ADDRESS: STREET 1: 300 PARK AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 FORMER COMPANY: FORMER CONFORMED NAME: APRICUS BIOSCIENCES, INC. DATE OF NAME CHANGE: 20100914 FORMER COMPANY: FORMER CONFORMED NAME: NEXMED INC DATE OF NAME CHANGE: 19970311 D 1 primary_doc.xml X0708 D LIVE 0001017491 SEELOS THERAPEUTICS, INC. 300 PARK AVENUE 12TH FLOOR NEW YORK NY NEW YORK 10017 (646) 998-6475 NEVADA APRICUS BIOSCIENCES, INC. NEXMED INC Corporation true Raj Mehra c/o Seelos Therapeutics, Inc. 300 Park Avenue, 12th Floor New York NY NEW YORK 10022 Executive Officer Director Brian Lian c/o Seelos Therapeutics, Inc. 300 Park Avenue, 12th Floor New York NY NEW YORK 10022 Director Richard W. Pascoe c/o Seelos Therapeutics, Inc. 300 Park Avenue, 12th Floor New York NY NEW YORK 10022 Director Judith Dunn c/o Seelos Therapeutics, Inc. 300 Park Avenue, 12th Floor New York NY NEW YORK 10022 Director Daniel J. O'Connor c/o Seelos Therapeutics, Inc. 300 Park Avenue, 12th Floor New York NY NEW YORK 10022 Director Biotechnology No Revenues 06b false 2020-09-09 false true true false 0 Roth Capital Partners, LLC 15407 None None 888 San Clemente Drive Suite 400 Newport Beach CA CALIFORNIA 92660 IL ILLINOIS FL FLORIDA NY NEW YORK false 5584950 0 5584950 Represents aggregate exercise price of warrants to purchase 6,648,750 shares of the Company's common stock, which were issued in connection with an offering of 8,865,000 shares of the Company's common stock issued in a registered direct offering. false 13 490235 80000 $490,234.50 is for a fee of 7.0% of the gross proceeds from the sale of securities in the registered direct offering and concurrent private placement of warrants, and up to $80,000 is for the reimbursement of expenses incurred by the placement agent. 0 false SEELOS THERAPEUTICS, INC. /s/ Raj Mehra, Ph.D. Raj Mehra, Ph.D. Chief Executive Officer and President 2020-09-14